{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:53:33Z","timestamp":1792011213895,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016223","name":"Wilmot Cancer Institute, University of Rochester Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","award":["P30CA272302"],"award-info":[{"award-number":["P30CA272302"]}],"id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urology.2026.09.053","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:52:57Z","timestamp":1790434377000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contrasting Reasons for Early Termination Between Industry and Non-Industry-Led Clinical Trials in Genitourinary Oncology"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3823","authenticated-orcid":false,"given":"Denzel","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Steidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-8987","authenticated-orcid":false,"given":"Kamil","family":"Malshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.09.053_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jama.290.1.113","article-title":"Industry funding of clinical trials: benefit or bias?","volume":"290","author":"Chopra","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.09.053_bib2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.urology.2026.09.053_bib3","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04204","article-title":"Academic vs. industry-sponsored trials: a global survey on differences, similarities, and future improvements","volume":"14","author":"Hoffmann","year":"2024","journal-title":"J Glob Health"},{"key":"10.1016\/j.urology.2026.09.053_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jama.2014.1361","article-title":"Prevalence, characteristics, and publication of discontinued randomized trials","volume":"311","author":"Kasenda","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.09.053_bib5","first-page":"Op2500194","article-title":"Impact of industry collaboration on US food and drug administration approval success in genitourinary malignancy phase III clinical trials","volume":"22","author":"Malshy","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.urology.2026.09.053_bib6","doi-asserted-by":"crossref","first-page":"g6870","DOI":"10.1136\/bmj.g6870","article-title":"Discontinuation and non-publication of surgical randomised controlled trials: observational study","volume":"349","author":"Chapman","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.urology.2026.09.053_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.24440","article-title":"Nonregistration, discontinuation, and nonpublication of randomized trials: a systematic review","volume":"8","author":"Speich","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2026.09.053_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/ACM.0b013e3182306440","article-title":"The prevalence and economic impact of low-enrolling clinical studies at an academic medical center","volume":"86","author":"Kitterman","year":"2011","journal-title":"Acad Med"},{"key":"10.1016\/j.urology.2026.09.053_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoto.2025.4766","article-title":"Clinical trial termination or withdrawal in head and neck squamous cell carcinoma","volume":"152","author":"Huang","year":"2026","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.urology.2026.09.053_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/JU.0000000000001072","article-title":"Clinical trials in urology: predictors of successes and failures","volume":"204","author":"Bandari","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.09.053_bib11","article-title":"Understanding the termination of urologic cancer clinical trials: insights and challenges","volume":"10","author":"Alhajahjeh","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.urology.2026.09.053_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/0003-4819-133-8-200010170-00013","article-title":"Better access to information about clinical trials","volume":"133","author":"McCray","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urology.2026.09.053_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103456","article-title":"Small biotechs versus large pharma: Who drives first-in-class innovation in oncology?","volume":"28","author":"Kennedy","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.urology.2026.09.053_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001191588.75314.0c.05","article-title":"IP15-05 Building a predictive nomogram to forcast completion of genitourinary oncology trials: insights from two decades of clinicaltrials.gov data","volume":"215","author":"Malshy","year":"2026","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.09.053_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/CCI.20.00031","article-title":"Assessing genitourinary cancer clinical trial accrual sufficiency using archived trial data","volume":"4","author":"Stensland","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.urology.2026.09.053_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7185","article-title":"Understanding the financial cost of cancer clinical trial participation","volume":"13","author":"Williams","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.urology.2026.09.053_bib17","unstructured":"Mural Health. Costs of clinical trial participation. Published May 5, 2025. Accessed Feb 2, 2026. https:\/\/www.muralhealth.com\/blog\/costs-of-clinical-trial-participation#:~:text=74%25%20of%20respondents%20enrolled%20in,over%20$25%2C000%20across%20their%20participation."},{"key":"10.1016\/j.urology.2026.09.053_bib18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jamaoncol.2020.1284","article-title":"Association of industry sponsorship with cancer clinical trial accrual","volume":"6","author":"Pasalic","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2026.09.053_bib19","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.24.00843","article-title":"Patient enrollment to industry-sponsored versus federally-sponsored cancer clinical trials","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2026.09.053_bib20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.urology.2026.09.053_bib21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.09.053_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","article-title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","volume":"25","author":"Bamias","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2026.09.053_bib23","first-page":"113","article-title":"The opportunity cost of capital: development of new pharmaceuticals","volume":"52","author":"Chit","year":"2015","journal-title":"Inquiry"},{"key":"10.1016\/j.urology.2026.09.053_bib24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2026.09.053_bib25","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1038\/s41598-025-88400-x","article-title":"Predicting accrual success for better clinical trial resource allocation","volume":"15","author":"Ma","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.urology.2026.09.053_bib26","article-title":"Master protocol design with hybrid control for efficient early-phase trial consolidation","volume":"9","author":"Kaizer","year":"2025","journal-title":"JCO Precis Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526006308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526006308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:39:00Z","timestamp":1792010340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526006308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0090429526006308"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.09.053","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contrasting Reasons for Early Termination Between Industry and Non-Industry-Led Clinical Trials in Genitourinary Oncology","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.09.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}